Teriparatide was continuously administrated. The intractable back pain subsided 2 weeks after teriparatide treatment. No additional VCF occurred, and the patient was symptom free at 33 months of follow-up.
In group B, four (18.18%) patients developed new-onset VCFs (five vertebrae) after the second PVP, and received a third PVP. Among those four patients, one (25%) developed new-onset VCFs after the third PVP and required a fourth PVP (Fig. 3). I-BET151 The new-onset VCFs involved six vertebrae: four were adjacent VCFs (67%), and two were non-adjacent VCFs. Surgical complications resulting in the need for additional PVPs (six vertebrae) included one major bone cement extravasation requiring decompressive laminectomy, and two minor bone cement extravasations. Muscle power in both legs of the patient who underwent decompressive laminectomy recovered gradually but not fully during a see more 6-month rehabilitation program. Overall, teriparatide reduced the risk of new-onset VCFs after vertebroplasty (OR = 0.21; 95% CI, 0.02–2.10). The fracture risk reduction associated with teriparatide treatment was markedly better than that with antiresorptive agents; the relative risk reduction was 78.57%. Fig. 3 The patient was a 74-year-old woman with severe osteoporosis (T-score, −3.70) who underwent PVP for T10 and T12 VCFs (a). A new-onset adjacent VCF at T9 occurred 68 days
after PVP, and the patient underwent a second PVP (b). The patient began alendronate treatment on the day the new-onset fracture was diagnosed. Flavopiridol cell line She experienced severe back pain again, and a plain lumbar spine X-ray demonstrated new L1 and L2 adjacent VCFs 43 days after the second PVP, so she underwent a third PVP due to intractable back pain (c). Unfortunately, a new T11 adjacent VCF occurred 33 days later, and a fourth PVP
was performed 2 weeks later, after which minor bone cement extravasation occurred (d) The BMD and T-score of Thymidylate synthase the lumbar spine were estimated prior to and after 6, 12, and 18 months of treatment. All 22 patients in group A underwent BMD examination before administration of teriparatide. One patient had an L2 VCF and an adjacent L3 VCF before treatment with teriparatide and experienced a new adjacent L1 VCF 27 days after starting therapy. Therefore, only the L4 vertebral body was not involved, so the BMD data were not included. One of the remaining 21 patients missed the 6-month BMD examination, and another missed the 12-month BMD examination. Three patients in group B had only one evaluable vertebral body for DXA examination, so the BMD data were excluded. Five patients skipped the 6-month, two skipped the 12-month, and two skipped the 18-month DXA examination. The remaining 19 patients had at least two evaluable BMD data for analysis. In group A, the mean BMD was 0.5796 ± 0.0816 g/cm2 at baseline, 0.6548 ± 0.1073 g/cm2 after 6 months, 0.